NYT picks apart ADHD

Share this article:

The New York Times gives a clinical and marketing look at the uptick in the $9-billion dollar attention deficit disorder market. Among the topics covered are the nomenclature for one of the condition's hallmark drugs—Adderall, which was a combination of A.D.D. and All—and the professional and consumer marketing strategies that have helped cultivate a prescriptive landscape that psychiatrist Keith Conners tells the Gray Lady “make it look like an epidemic. Well, it's not. It's preposterous.”

The piece also touches on the prickly topic of pharmaceutical-sponsored speaking engagements (one industry-compensated orator says company money has not influenced his research) and patient-facing materials about ADHD surfacing in at least one school system as well as the relatively recent wave of adult ADHD awareness messaging, among other topics.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.